Ovarian cancer stem cells identified, characterized

Apr 17, 2008

Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer’s recurrence and its resistance to chemotherapy.

“These results bring us closer to more effective and targeted treatment for epithelial ovarian cancer, one of the most lethal forms of cancer,” said Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine.

Mor presented his findings recently at the annual meeting of the American Association for Cancer Research (AACR) Meeting in San Diego, California.

Cancerous tumors are made up of cells that are both cancerous and non-cancerous. Within cancerous cells, there is a further subclass referred to as cancer stem cells, which can replicate indefinitely.

“Present chemotherapy modalities eliminate the bulk of the tumor cells, but cannot eliminate a core of these cancer stem cells that have a high capacity for renewal,” said Mor, who is also a member of the Yale Cancer Center. “Identification of these cells, as we have done here, is the first step in the development of therapeutic modalities.”

Mor and colleagues isolated cells from 80 human samples of either peritoneal fluid or solid tumors. The cancer stem cells that were identified were positive for traditional cancer stem cell markers including CD44 and MyD88. These cells also showed a high capacity for repair and self-renewal.

The isolated cells formed tumors 100 percent of the time. Within those tumors, 10 percent of the cells were positive for cancer stem cell marker CD44, while 90 percent were CD44 negative.

Mor and his team were able to isolate and clone the ovarian cancer stem cells. They found that these cells were highly resistant to conventional chemotherapy while the non-cancer stem cells responded to treatment. “Isolating and cloning these cells will lead to development of new treatments to target and eliminate the cancer stem cells and hopefully prevent recurrence,” said Mor.

Source: Yale University

Explore further: Population-based FIT screening can reduce CRC mortality

Related Stories

New insight into lethal fungus infection in wildlife

May 21, 2015

The introduction of a lethal fungus infection that could threaten the UK's amphibian populations has not been caused by exposure to infected colonies of African clawed frogs, according to new research from ...

Dying cells can protect their stem cells from destruction

May 11, 2015

Cells dying as the result of radiation exposure or chemotherapy can send a warning to nearby stem cells. The chemical signal allows the stem cells to escape the same fate, University of Washington researchers ...

Recommended for you

Population-based FIT screening can reduce CRC mortality

15 hours ago

(HealthDay)—Population-based fecal immunochemical testing (FIT) screening in adults aged 50 to 69 years can reduce colorectal cancer (CRC) mortality, according to a study published online May 20 in Cancer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.